Universe Pharmaceuticals (UPC) Liabilities and Shareholders Equity (2020 - 2025)

Universe Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $69.3 billion for Q3 2025.

• Liabilities and Shareholders Equity for Q3 2025 came in at $69.3 billion, up 1.99% year-over-year; the trailing twelve-month figure through Sep 2025 was $137.3 billion (up 101.64% YoY), and the FY2025 annual result was $69.3 billion, up 1.99% from the prior year.
• Liabilities and Shareholders Equity came in at $69.3 billion for Q3 2025 at Universe Pharmaceuticals, up from $68.0 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $69.3 billion in Q3 2025 to a low of $41.7 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $70.3 million (2021), against an average of $17.2 billion.
• Across the five-year window, Liabilities and Shareholders Equity surged 243521825.1% in 2021 and retreated 29.92% in 2023, its largest moves.
• Universe Pharmaceuticals' Liabilities and Shareholders Equity stood at $70.1 million in 2021, then decreased by 15.12% to $59.5 million in 2022, then declined by 29.92% to $41.7 million in 2023, then soared by 162762.16% to $68.0 billion in 2024, then climbed by 1.99% to $69.3 billion in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $69.3 billion (Q3 2025), $68.0 billion (Q3 2024), and $49.4 million (Q1 2024), per Business Quant data.